Swiss drug giant Novartis has secured an injunction temporarily blocking drug maker Pharmacor from launching a generic version of the company’s top-selling MS drug Gilenya in Australia.
A director of sunglasses company Quay Eyewear has lost her bid to access HWL Ebsworth’s advice to the company given during legal proceedings which accused her of tortious interference, breach of directors’ duties and intellectual property violations.
Buffet dining pioneer Sizzler, which closed its last Australian restaurants in November, has settled a trade mark dispute with Brisbane-based chain Burger Urge over a chicken burger known as “the Sizzle”.
Global property giant REA Group has blocked a trade mark application by Real Estate Store, a new venture of a former director of Reserve Hotel Group, with IP Australia finding there was a “real and tangible danger” that consumers would think the companies were connected.
Building and construction information service provider BCI Media is suing CoreLogic, accusing the property data analytics company of unauthorised access and scraping confidential information from its copyright-protected leads platform.
The Rolling Stones has successfully opposed registration of the ‘Jagger & Stone’ clothing trade mark in Australia, with a delegate finding the name was designed to “springboard” off the UK rock band’s worldwide fame.
A judge has denied an application by industrial filter manufacturer Laminar Air Flow to add a new respondent in a long-running trade mark dispute against rival Vokes Ltd, with a judge finding the company had provided no explanation as to why the bid was made just four months before trial.
Food giants Arnott’s and Campbell will stop using their ‘Plantly’ logo on any new products pending the resolution of a trade mark infringement lawsuit brought by rival Goodman Fielder.
Cosmetics giant L’Oreal has lost its opposition to Melbourne-based Lore Perfumery’s ‘Lore’ trade mark, with an IP Australia delegate finding that L’Oreal’s strong reputation made it unlikely that consumers would be deceived or confused.
A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.